Clinical trials: Type 1 Diabetes Mellitus Maturity Onset
Diabetes Mellitus, Diabetes Mellitus, Type 2
Single Dose Study of PF-04991532 in Healthy Subjects
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK) and preliminary food effect of PF-04991532 following single escalating oral doses in healthy adult subjects.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
- Trial name
- NCT01102673
- Testing
- PF-04991532
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 1 Diabetes Mellitus Maturity Onset
Smartguard Use in Real Life : a Longitudinal Study in Patients With Type 1 Diabetes
The reference treatment of the type 1 diabetes is intensified insulin therapy by insulin pump. The CGM (continuous glucose monitoring) is a technology available for a decade, which allows the continuous measure of interstitial…
- Trial name
- Smartguard (NCT03047486)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Caen
Diabetes Mellitus, Type 2
A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
To compare short-term efficacy and safety of Exubera vs Lantus in patients with type 2 diabetes mellitus
- Trial name
- NCT00367445
- Testing
- Inhaled Human Insulin (Exubera), Insulin Glargine (Lantus)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Japanese Phase 1 Multiple Ascending Dose Study
The purpose of this clinical study is to assess the safety and tolerability of multiple oral doses of BMS-823778 in healthy Japanese subjects and Japanese patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01515202
- Testing
- BMS-823778
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus
Effect of Dosing Time and Meal on IN-105 (Insulin Tregopil) PK and PD
A study to evaluate the PK and PD of oral IN-105 (Insulin Tregopil) w.r.t. time of dosing prior to meal, duration between meals and type of meal .
- Trial name
- NCT03392961
- Testing
- IN-105 (Insulin Tregopil)
- Volunteers
- 51 people
- Sponsor
- Biocon Limited
Diabetes Mellitus, Non-Insulin-Dependent
NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes
The purpose of this research study is to investigate the mechanism of action of a new investigational medication (drug), NNC 90-1170, which is being developed for the treatment of type 2 diabetes (adult onset type of diabetes.
- Trial name
- NCT00013910
- Testing
- NNC 90-1170
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Type 1 Diabetes, Type 2 Diabetes
Blood Glucose Response to Meals of Varying Glycemic Index in Youth With Type 1 & 2 Diabetes
Research to date suggests that the selection of lower glycemic index foods, that is, foods provoking a slower, more sustained blood sugar response, may result in improved glycemic control in youth with diabetes.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Impaired Glucose Metabolism
- Trial name
- NCT00545727
- Testing
- Diet, Standard diet
- Volunteers
- 36 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Healthy
A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
The purpose of this study is to assess the bioequivalence (similarity of the drug amount in blood among the formulations) of the fixed dose combination (two components combined in one tablet) of canagliflozin and metformin…
- Trial name
- NCT02077803
- Testing
- Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes
An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System
A multi-center, single-arm, open-label study to evaluate the safety and effectiveness of the EndoBarrier Gastrointestinal Liner System liner on glycemic control in control subjects from study #09-1 who are not treatment failures…
- Trial name
- OLE (NCT02293720)
- Testing
- EndoBarrier
- Sponsor
- Morphic Medical Inc.
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers
This is a phase 1 study to demonstrate pharmacokinetic and pharmacodynamic similarity between HEC-Glargine and US-Lantus® using the euglycemic clamp technique in healthy male adult volunteers.
- Trial name
- NCT05248841
- Testing
- HEC-Glargine, US-Lantus
- Where
- South Africa
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Lannett Company, Inc.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
- Trial name
- NCT00476931
- Testing
- SB-509
- Where
- 20 sites in United States, Mexico
- Volunteers
- 91 people
- Sponsor
- Sangamo Therapeutics
Type 2 Diabetes
Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the pharmacokinetics, tolerability, and safety of single and multiple doses of exenatide once-weekly suspension via subcutaneous (SC) injection using a pre-filled, single-dose autoinjector…
- Trial name
- NCT04001231
- Testing
- Exenatide Once-Weekly Suspension
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)
This study will evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of ertugliflozin following oral administration of unlabeled ertugliflozin (MK-8835) and intravenous (IV) and oral administration of…
- Trial name
- NCT02411929
- Testing
- Unlabeled ertugliflozin for oral use, 14^C-labeled ertugliflozin for IV use, 14^C-labeled ertugliflozin for oral use
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes
The objective of the study is to test the efficacy, safety and tolerability of several doses of BI 1356 BS (1, 5, or 10 mg taken once daily) compared to placebo given for 12 weeks together with metformin in patients with type 2…
- Trial name
- NCT00309608
- Testing
- Linagliptin, Glimepiride
- Where
- 48 sites in France, Germany and 4 more
- Volunteers
- 333 people
- Sponsor
- Boehringer Ingelheim
Diabetes (DM), Diabetic Ketoacidosis
Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes
Diabetic ketoacidosis (DKA) is increasingly recognized in adults with "ketone-prone" type 2 diabetes. In many of these patients, the pancreas can still make insulin but becomes temporarily "stunned" during severe, prolonged high…
- Conditions
- Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
- Trial name
- NCT07167693
- Testing
- Arginine hydrochloride, Sodium Chloride 0.9%
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- David K Carroll
Diabetes, Diabetes Mellitus, Type 1
GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus
This study is conducted in Asia, Europe and in the United States of America. The aim of this study is to examine patient and physician beliefs regarding insulin therapy and the degree to which patients adhere to their insulin…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01950650
- Testing
- No treatment given, survey
- Where
- 10 sites in United States, China and 8 more
- Volunteers
- 1,800 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Taiwan
This study is conducted in Asia. The aim of this observational study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in Asia.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare Asia (NCT00887874)
- Testing
- No treatment given
- Where
- Taiwan
- Volunteers
- 2,370 people
- Sponsor
- Novo Nordisk A/S
Prediabetes, Diabetes Type 1
An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms
G (guanine nucleotide binding) proteins associating with G protein-coupled receptors (GPCR) are key players in the pathogenesis of obesity and diabetes and are targets of pharmacotherapeutic inter-ventions.
- Conditions
- Prediabetes, Diabetes Type 1, Diabetes Type 2
- Trial name
- NCT02057497
- Volunteers
- healthy volunteers welcome
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Diabetes Mellitus
Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
This is a safety and dose finding efficacy study to evaluate the effects of BGP-15 over the dose range of 100 mg/day to 400 mg/day.
- Trial name
- NCT01069965
- Testing
- BGP-15 100 mg QD, BGP-15 100 mg BID, BGP-15 200 mg QD
- Where
- 30 sites in United States, Germany and 1 more
- Volunteers
- 196 people
- Sponsor
- N-Gene Research Laboratories, Inc.
Diabetes Mellitus Type 1, Diabetes Mellitus Type 2
Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals
Patients with diabetes have high blood sugar levels (hyperglycemia) because pancreatic beta-cells no longer produce sufficient insulin.
- Trial name
- NCT00813228
- Testing
- Sitagliptin (Januvia)
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)